marble bone disease

(redirected from Malignant Osteopetrosis)
Also found in: Medical.

marble bone disease

[′mär·bəl ¦bōn di‚zēz]
(medicine)
Mentioned in ?
References in periodicals archive ?
The loci of malignant osteopetrosis should fall on a homozygous chromosomal region because the parents are consanguineous.
Prenatal diagnosis of malignant osteopetrosis in Bedouin families by linkage analysis.
Novel mutations in Indian patients with autosomal recessive infantile malignant osteopetrosis.
InterMune currently markets ACTIMMUNE(R) (Interferon gamma-1b) Injection in the United States for the treatment of chronic granulomatous disease (CGD) and severe, malignant osteopetrosis and is in Phase III clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF) and multidrug-resistant tuberculosis (MDR TB).
Autosomal recessive malignant osteopetrosis (ARO; arOP) is a serious lethal disorder usually leading to death in infancy and childhood.
TCIRGl appears to be an important gene for autosomal recessive malignant osteopetrosis in India, similar to the data for other populations available in the literature.
InterMune markets Actimmune(R) for the treatment of two life-threatening congenital diseases: chronic granulomatous disease and severe, malignant osteopetrosis.
Severe, malignant osteopetrosis is a life-threatening congenital disorder in which an overgrowth of bony structures leads to blindness, deafness and increased susceptibility to infection.
InterMune will continue to support the supply and reimbursement of Actimmune(R) (interferon gamma-1b) for its labeled indications, chronic granulomatous disease (CGD) and severe, malignant osteopetrosis, and expects that given the lack of approved treatments, revenue from physician prescriptions of Actimmune(R) for the treatment of IPF will continue to be significant.
InterMune markets Actimmune(R) for the treatment of two life- threatening congenital diseases: chronic granulomatous disease and severe, malignant osteopetrosis.
InterMune markets Actimmune for the treatment of two life- threatening congenital diseases: chronic granulomatous disease and severe, malignant osteopetrosis.
InterMune markets Actimmune for the treatment of two life-threatening congenital diseases: chronic granulomatous disease and severe, malignant osteopetrosis.

Full browser ?